Literature DB >> 24351681

TCEB3C a putative tumor suppressor gene of small intestinal neuroendocrine tumors.

Katarina Edfeldt1, Tanveer Ahmad, Göran Åkerström, Eva Tiensuu Janson, Per Hellman, Peter Stålberg, Peyman Björklund, Gunnar Westin.   

Abstract

Small intestinal neuroendocrine tumors (SI-NETs), formerly known as midgut carcinoids, are rare and slow-growing neoplasms. Frequent loss of one copy of chromosome 18 in primary tumors and metastases has been observed. The aim of the study was to investigate a possible role of TCEB3C (Elongin A3), currently the only imprinted gene on chromosome 18, as a tumor suppressor gene in SI-NETs, and whether its expression is epigenetically regulated. Primary tumors, metastases, the human SI-NET cell line CNDT2.5, and two other cell lines were included. Immunohistochemistry, gene copy number determination by PCR, colony formation assay, western blotting, real-time quantitative RT-PCR, RNA interference, and quantitative CpG methylation analysis by pyrosequencing were performed. A large majority of tumors (33/43) showed very low to undetectable Elongin A3 expression and as expected 89% (40/45) displayed one gene copy of TCEB3C. The DNA hypomethylating agent 5-aza-2'-deoxycytidine induced TCEB3C expression in CNDT2.5 cells, in primary SI-NET cells prepared directly after surgery, but not in two other cell lines. Also siRNA to DNMT1 and treatment with the general histone methyltransferase inhibitor 3-deazaneplanocin A induced TCEB3C expression in a cell type-specific way. CpG methylation at the TCEB3C promoter was observed in all analyzed tissues and thus not related to expression. Overexpression of TCEB3C resulted in a 50% decrease in clonogenic survival of CNDT2.5 cells, but not of control cells. The results support a putative role of TCEB3C as a tumor suppressor gene in SI-NETs. Epigenetic repression of TCEB3C seems to be tumor cell type-specific and involves both DNA and histone methylation.

Entities:  

Keywords:  LOH; carcinoid; elongation; epigenetic; imprinting

Mesh:

Substances:

Year:  2014        PMID: 24351681     DOI: 10.1530/ERC-13-0419

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  11 in total

1.  Primary carcinoid tumor of medulla spinalis: case report and review of the literature.

Authors:  Xian-feng Zhang; Yan Zhang; Xu Yan; Li Bie
Journal:  Eur J Med Res       Date:  2014-12-19       Impact factor: 2.175

2.  A plausible role for actin gamma smooth muscle 2 (ACTG2) in small intestinal neuroendocrine tumorigenesis.

Authors:  Katarina Edfeldt; Per Hellman; Gunnar Westin; Peter Stalberg
Journal:  BMC Endocr Disord       Date:  2016-04-23       Impact factor: 2.763

3.  A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors.

Authors:  Jan P Dumanski; Chiara Rasi; Peyman Björklund; Hanna Davies; Abir S Ali; Malin Grönberg; Staffan Welin; Halfdan Sorbye; Henning Grønbæk; Janet L Cunningham; Lars A Forsberg; Lars Lind; Erik Ingelsson; Peter Stålberg; Per Hellman; Eva Tiensuu Janson
Journal:  Endocr Relat Cancer       Date:  2017-06-20       Impact factor: 5.678

Review 4.  NETs: organ-related epigenetic derangements and potential clinical applications.

Authors:  Mauro Cives; Valeria Simone; Francesca Maria Rizzo; Franco Silvestris
Journal:  Oncotarget       Date:  2016-08-30

5.  Molecular prognostic factors in small-intestinal neuroendocrine tumours.

Authors:  K G Samsom; L M van Veenendaal; G D Valk; M R Vriens; M E T Tesselaar; J G van den Berg
Journal:  Endocr Connect       Date:  2019-07       Impact factor: 3.335

Review 6.  Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms.

Authors:  Johannes Hofland; Gregory Kaltsas; Wouter W de Herder
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

Review 7.  Clinical Epigenetics of Neuroendocrine Tumors: The Road Ahead.

Authors:  Annamaria Colao; Filomena de Nigris; Roberta Modica; Claudio Napoli
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-15       Impact factor: 5.555

Review 8.  Clinical Features, Management, and Molecular Characteristics of Familial Small Bowel Neuroendocrine Tumors.

Authors:  James Y Lim; Rodney F Pommier
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-26       Impact factor: 5.555

Review 9.  Epigenetics of gastroenteropancreatic neuroendocrine tumors: A clinicopathologic perspective.

Authors:  Brendan M Finnerty; Katherine D Gray; Maureen D Moore; Rasa Zarnegar; Thomas J Fahey Iii
Journal:  World J Gastrointest Oncol       Date:  2017-09-15

10.  Decrease of 5-hydroxymethylcytosine and TET1 with nuclear exclusion of TET2 in small intestinal neuroendocrine tumors.

Authors:  Elham Barazeghi; Surendra Prabhawa; Olov Norlén; Per Hellman; Peter Stålberg; Gunnar Westin
Journal:  BMC Cancer       Date:  2018-07-25       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.